Biopharmaceuticals are becoming a significant treatment options for a wide array of diseases. However, their complexity and large size complicates their production. In addition, with the expiration of patents for several biologics, interest in the development of similar products (biosimilars) have risen and generated new challenges for approval; the most important being to prove the full similarity to the original biologic. Manufacturing of biotherapeutics is a complex process that presents similar challenges as protein crystallization, both in terms of formulation and stability. We can therefore apply similar analytical procedures to help manufacturers of biotherapeutics achieve the highest stability of their final product.